Impact of psilocybin and Psilocybe cubensis extract on gut microbiota in Wistar Han rats
DOI:
https://doi.org/10.48797/sl.2026.492Keywords:
PosterAbstract
Background: Psilocybin, the main psychoactive compound found in Psilocybe mushrooms, has gained increasing attention due to its potential therapeutic effects in neuropsychiatric disorders [1]. Beyond its central effects, increasing evidence highlights the relevance of the gut–brain axis, suggesting that psychedelics may also influence intestinal microbiota composition. Whole mushroom extracts contain additional bioactive compounds that may modulate these effects, yet comparative preclinical data between pure psilocybin and mushroom extracts remain limited [2,3]. Objective: To evaluate the impact of pure psilocybin and Psilocybe cubensis extract on gut microbiota in vivo. Methods: Eighteen male Wistar Han rats (250–275 g; 8–9 weeks old) were randomly assigned to three groups (n=6): control (0.9% NaCl), psilocybin (3 mg·kg⁻¹), and P. cubensis extract (equivalent to 3 mg·kg⁻¹ psilocybin/psilocin). Treatments were administered by oral gavage (0.5 mL·kg⁻¹). Fecal samples were collected at baseline (T1) and at days 7 (T7) and 14 (T14) post-exposure for microbiota analysis. Microbial profiling was performed using long-read amplicon sequencing targeting the full-length 16S rRNA gene. Libraries were prepared using SMRTbell technology and sequenced on the PacBio platform. Bioinformatic analysis enabled high-resolution taxonomic assignment and reconstruction of microbial community structure, improving species-level identification accuracy. Statistical analysis included ANOVA and multivariate analysis of beta-diversity (p<0.05). All procedures were approved by the institutional Animal Welfare Committee and DGAV, in accordance with European and national legislation. Results: Baseline microbiota composition (T1) was similar across all groups, clustering closely together, as expected prior to treatment. This profile remained comparable to the control group at T7 and T14. In contrast, distinct shifts in microbial community structure were observed in treated groups. Both psilocybin and P. cubensis extract induced separation from baseline and control profiles at T7, with further divergence at T14. This effect was more pronounced in the psilocybin group, which exhibited the greatest distance in cluster analysis, indicating a stronger impact on microbiota composition. Conclusions: These findings suggest a time-dependent modulation of gut microbiota induced by both treatments, with differential magnitude between the pure compound and the whole extract.References
1. Erkizia-Santamaría, I. et al. Role of endogenous serotonin in psychedelic-like effects of psilocybin in mice. Int J Neuropsychopharmacol 2025, 28(6), pyaf035, doi:10.1093/ijnp/pyaf035.
2. Ali, A. et al. Natural vs. synthetic psilocybin: The same or completely different? In Mushrooms with Therapeutic Potentials: Recent Advances in Research and Development; Springer Nature: Singapore, 2023; pp. 479–492, doi:10.1007/978-981-19-9550-7_18.
3. Johnson-Groh, M. Addressing a critical knowledge gap in psychedelic research. ACS Cent Sci 2025, 11(8), 1256–126.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Francisco Sacadura, Cláudia Marques, Andreia Machado Brito-da-Costa, Mariana Carvalho, Helena Carmo, Ricardo Jorge Dinis-Oliveira, Áurea Madureira-Carvalho, Diana Dias da Silva

This work is licensed under a Creative Commons Attribution 4.0 International License.
In Scientific Letters, articles are published under a CC-BY license (Creative Commons Attribution 4.0 International License), the most open license available. The users can share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material for any purpose, even commercially), as long as they give appropriate credit, provide a link to the license, and indicate if changes were made (read the full text of the license terms and conditions of use).
The author is the owner of the copyright.






